← All trials
NCT04504240
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2020
- Primary completion
- Oct 30, 2020
- Completion date
- Oct 30, 2020
- First posted
- Aug 7, 2020
- Last posted
- Aug 11, 2020
- Enrollment
- 200
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Chattogram General HospitalLead sponsor
- Jiao Tong UniversityReponsible party - principal investigator
- Jiao Tong UniversityStudy director
- Jiao Tong UniversityStudy chair
- Jiao Tong UniversityCollaborator
- M Abdur Rahim Medical College and HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.